LRP4 in neuromuscular junction and bone development and diseases

Bone

Volumn 80, Issue , 2015, Pages 101-108

  Shen, Chengyong ^a   Xiong, Wen Cheng ^a   Mei, Lin ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Bone; Low density lipoprotein receptor related protein 4; Myasthenia gravis; Neuromuscular junction

Indexed keywords

AUTOANTIBODY; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 4; UNCLASSIFIED DRUG; LRP4 PROTEIN, HUMAN;

AMYOTROPHIC LATERAL SCLEROSIS; ANTIBODY DETECTION; BONE DEVELOPMENT; BONE DISEASE; CELL DIFFERENTIATION; HUMAN; INTRON; MORPHOGENESIS; MUSCLE ACTION POTENTIAL; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; ANIMAL; METABOLISM; NEUROMUSCULAR JUNCTION; PHYSIOLOGY;

ANIMALS; BONE DEVELOPMENT; HUMANS; LDL-RECEPTOR RELATED PROTEINS; NEUROMUSCULAR JUNCTION;

EID: 84943663820     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2015.05.012     Document Type: Review

References (80)

1. Nakayama M., Nakajima D., Nagase T., Nomura N., Seki N., Ohara O. Identification of high-molecular-weight proteins with multiple EGF-like motifs by motif-trap screening. Genomics 1998, 51:27-34.
2. Tian Q.B., Nakayama K., Okano A., Suzuki T. Identification of mRNAs localizing in the postsynaptic region. Brain Res Mol Brain Res 1999, 72:147-157.
3. Suzuki T. Identification of novel PSD proteins and their possible functions. Nihon Shinkei Seishin Yakurigaku Zasshi 2004, 24:205-210.
4. Leupin O., Piters E., Halleux C., Hu S., Kramer I., Morvan F., et al. Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J Biol Chem 2011, 286:19489-19500.
5. Li Y., Pawlik B., Elcioglu N., Aglan M., Kayserili H., Yigit G., et al. LRP4 mutations alter Wnt/beta-catenin signaling and cause limb and kidney malformations in Cenani-Lenz syndrome. Am J Hum Genet 2010, 86:696-706.
6. Tomita Y., Kim D.H., Magoori K., Fujino T., Yamamoto T.T. A novel low-density lipoprotein receptor-related protein with type II membrane protein-like structure is abundant in heart. J Biochem 1998, 124:784-789.
7. Herz J., Bock H.H. Lipoprotein receptors in the nervous system. Annu Rev Biochem 2002, 71:405-434.
8. McMahan U.J. The agrin hypothesis. Cold Spring Harb Symp Quant Biol 1990, 55:407-418.
9. DeChiara T.M., Bowen D.C., Valenzuela D.M., Simmons M.V., Poueymirou W.T., Thomas S., et al. The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo. Cell 1996, 85:501-512.
10. Gautam M., Noakes P.G., Moscoso L., Rupp F., Scheller R.H., Merlie J.P., et al. Defective neuromuscular synaptogenesis in agrin-deficient mutant mice. Cell 1996, 85:525-535.
11. Glass D.J., Bowen D.C., Stitt T.N., Radziejewski C., Bruno J., Ryan T.E., et al. Agrin acts via a MuSK receptor complex. Cell 1996, 85:513-523.
12. Bowe M.A., Deyst K.A., Leszyk J.D., Fallon J.R. Identification and purification of an agrin receptor from Torpedo postsynaptic membranes: a heteromeric complex related to the dystroglycans. Neuron 1994, 12:1173-1180.
13. Campanelli J.T., Roberds S.L., Campbell K.P., Scheller R.H. A role for dystrophin-associated glycoproteins and utrophin in agrin-induced AChR clustering. Cell 1994, 77:663-674.
14. Gee S.H., Montanaro F., Lindenbaum M.H., Carbonetto S. Dystroglycan-alpha, a dystrophin-associated glycoprotein, is a functional agrin receptor. Cell 1994, 77:675-686.
15. Hilgenberg L.G., Su H., Gu H., O'Dowd D.K., Smith M.A. Alpha3Na+/K+-ATPase is a neuronal receptor for agrin. Cell 2006, 125:359-369.
16. Wang Q., Zhang B., Wang Y.E., Xiong W.C., Mei L. The Ig1/2 domain of MuSK binds to muscle surface and is involved in acetylcholine receptor clustering. Neurosignals 2008, 16:246-253.
17. Weatherbee S.D., Anderson K.V., Niswander L.A. LDL-receptor-related protein 4 is crucial for formation of the neuromuscular junction. Development 2006, 133:4993-5000.
18. Kim N., Stiegler A.L., Cameron T.O., Hallock P.T., Gomez A.M., Huang J.H., et al. Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell 2008, 135:334-342.
19. Zhang B., Luo S., Wang Q., Suzuki T., Xiong W.C., Mei L. LRP4 serves as a coreceptor of agrin. Neuron 2008, 60:285-297.
20. Zhang W., Coldefy A.S., Hubbard S.R., Burden S.J. Agrin binds to the N-terminal region of Lrp4 protein and stimulates association between Lrp4 and the first immunoglobulin-like domain in muscle-specific kinase (MuSK). J Biol Chem 2011, 286:40624-40630.
21. Zong Y., Zhang B., Gu S., Lee K., Zhou J., Yao G., et al. Structural basis of agrin-LRP4-MuSK signaling. Genes Dev 2012, 26:247-258.
22. Cornish T., Chi J., Johnson S., Lu Y., Campanelli J.T. Globular domains of agrin are functional units that collaborate to induce acetylcholine receptor clustering. J Cell Sci 1999, 112(Pt 8):1213-1223.
23. Gesemann M., Denzer A.J., Ruegg M.A. Acetylcholine receptor-aggregating activity of agrin isoforms and mapping of the active site. J Cell Biol 1995, 128:625-636.
24. Hopf C., Hoch W. Dimerization of the muscle-specific kinase induces tyrosine phosphorylation of acetylcholine receptors and their aggregation on the surface of myotubes. J Biol Chem 1998, 273:6467-6473.
25. Wu H., Lu Y., Shen C., Patel N., Gan L., Xiong W.C., et al. Distinct roles of muscle and motoneuron LRP4 in neuromuscular junction formation. Neuron 2012, 75:94-107.
26. Johnson E.B., Hammer R.E., Herz J. Abnormal development of the apical ectodermal ridge and polysyndactyly in Megf7-deficient mice. Hum Mol Genet 2005, 14:3523-3538.
27. Choi H.Y., Liu Y., Tennert C., Sugiura Y., Karakatsani A., Kroger S., et al. APP interacts with LRP4 and agrin to coordinate the development of the neuromuscular junction in mice. Elife 2013, 2:e00220.
28. Gomez A.M., Burden S.J. The extracellular region of Lrp4 is sufficient to mediate neuromuscular synapse formation. Dev Dyn 2011, 240:2626-2633.
29. Selvais C., D'Auria L., Tyteca D., Perrot G., Lemoine P., Troeberg L., et al. Cell cholesterol modulates metalloproteinase-dependent shedding of low-density lipoprotein receptor-related protein-1 (LRP-1) and clearance function. FASEB J. 2011, 25:2770-2781.
30. von Arnim C.A., Kinoshita A., Peltan I.D., Tangredi M.M., Herl L., Lee B.M., et al. The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate. J Biol Chem 2005, 280:17777-17785.
31. Willnow T.E., Moehring J.M., Inocencio N.M., Moehring T.J., Herz J. The low-density-lipoprotein receptor-related protein (LRP) is processed by furin in vivo and in vitro. Biochem J 1996, 313(Pt 1):71-76.
32. Yumoto N., Kim N., Burden S.J. Lrp4 is a retrograde signal for presynaptic differentiation at neuromuscular synapses. Nature 2012, 489:438-442.
33. Bogdanik L.P., Burgess R.W. A valid mouse model of AGRIN-associated congenital myasthenic syndrome. Hum Mol Genet 2011, 20:4617-4633.
34. Chevessier F., Girard E., Molgo J., Bartling S., Koenig J., Hantai D., et al. A mouse model for congenital myasthenic syndrome due to MuSK mutations reveals defects in structure and function of neuromuscular junctions. Hum Mol Genet 2008, 17:3577-3595.
35. Hesser B.A., Henschel O., Witzemann V. Synapse disassembly and formation of new synapses in postnatal muscle upon conditional inactivation of MuSK. Mol Cell Neurosci 2006, 31:470-480.
36. Barik A., Lu Y., Sathyamurthy A., Bowman A., Shen C., Li L., et al. LRP4 is critical for neuromuscular junction maintenance. J Neurosci 2014, 34:13892-13905.
37. Ohkawara B., Cabrera-Serrano M., Nakata T., Milone M., Asai N., Ito K., et al. LRP4 third beta-propeller domain mutations cause novel congenital myasthenia by compromising agrin-mediated MuSK signaling in a position-specific manner. Hum Mol Genet 2014, 23:1856-1868.
38. Lindstrom J.M., Seybold M.E., Lennon V.A., Whittingham S., Duane D.D. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976, 26:1054-1059.
39. Vincent A., Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 1985, 48:1246-1252.
40. Hoch W., McConville J., Helms S., Newsom-Davis J., Melms A., Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001, 7:365-368.
41. Sanders D.B., El-Salem K., Massey J.M., McConville J., Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003, 60:1978-1980.
42. Gasperi C., Melms A., Schoser B., Zhang Y., Meltoranta J., Risson V., et al. Anti-agrin autoantibodies in myasthenia gravis. Neurology 2014, 82:1976-1983.
43. Higuchi O., Hamuro J., Motomura M., Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 2011, 69:418-422.
44. Pevzner A., Schoser B., Peters K., Cosma N.C., Karakatsani A., Schalke B., et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol 2012, 259:427-435.
45. Zhang B., Shen C., Bealmear B., Ragheb S., Xiong W.C., Lewis R.A., et al. Autoantibodies to agrin in myasthenia gravis patients. PLoS One 2014, 9:e91816.
46. Zhang B., Tzartos J.S., Belimezi M., Ragheb S., Bealmear B., Lewis R.A., et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 2012, 69:445-451.
47. Shen C., Lu Y., Zhang B., Figueiredo D., Bean J., Jung J., et al. Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis. J Clin Invest 2013, 123:5190-5202.
48. Tzartos J.S., Zisimopoulou P., Rentzos M., Karandreas N., Zouvelou V., Evangelakou P., et al. LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients. Ann Clin Transl Neurol 2014, 1:80-87.
49. Perez-Garcia M.J., Burden S.J. Increasing MuSK activity delays denervation and improves motor function in ALS mice. Cell Rep 2012, 2:497-502.
50. Simon-Chazottes D., Tutois S., Kuehn M., Evans M., Bourgade F., Cook S., et al. Mutations in the gene encoding the low-density lipoprotein receptor LRP4 cause abnormal limb development in the mouse. Genomics 2006, 87:673-677.
51. Karner C.M., Dietrich M.F., Johnson E.B., Kappesser N., Tennert C., Percin F., et al. Lrp4 regulates initiation of ureteric budding and is crucial for kidney formation-a mouse model for Cenani-Lenz syndrome. PLoS One 2010, 5:e10418.
52. Lindy A.S., Bupp C.P., McGee S.J., Steed E., Stevenson R.E., Basehore M.J., et al. Truncating mutations in LRP4 lead to a prenatal lethal form of Cenani-Lenz syndrome. Am J Med Genet A 2014, 164A:2391-2397.
53. Drogemuller C., Leeb T., Harlizius B., Tammen I., Distl O., Holtershinken M., et al. Congenital syndactyly in cattle: four novel mutations in the low density lipoprotein receptor-related protein 4 gene (LRP4). BMC Genet 2007, 8:5.
54. Johnson E.B., Steffen D.J., Lynch K.W., Herz J. Defective splicing of Megf7/Lrp4, a regulator of distal limb development, in autosomal recessive mulefoot disease. Genomics 2006, 88:600-609.
55. Rivadeneira F., Styrkarsdottir U., Estrada K., Halldorsson B.V., Hsu Y.H., Richards J.B., et al. Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat Genet 2009, 41:1199-1206.
56. Chang M.K., Kramer I., Huber T., Kinzel B., Guth-Gundel S., Leupin O., et al. Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels. Proc Natl Acad Sci U S A 2014, 111:5187-5195.
57. Xiong L., Jung J.U., Wu H., Xia W.F., Pan J.X., Shen C., et al. Lrp4 in osteoblasts suppresses bone formation and promotes osteoclastogenesis and bone resorption. Proc Natl Acad Sci U S A 2015, 112:3487-3492.
58. May P., Herz J. LDL receptor-related proteins in neurodevelopment. Traffic 2003, 4:291-301.
59. Choi H.Y., Dieckmann M., Herz J., Niemeier A. Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo. PLoS One 2009, 4:e7930.
60. Ohazama A., Johnson E.B., Ota M.S., Choi H.Y., Porntaveetus T., Oommen S., et al. Lrp4 modulates extracellular integration of cell signaling pathways in development. PLoS One 2008, 3:e4092.
61. Zhang B., Liang C., Bates R., Yin Y., Xiong W.C., Mei L. Wnt proteins regulate acetylcholine receptor clustering in muscle cells. Mol Brain 2012, 5:7.
62. Gotthardt M., Trommsdorff M., Nevitt M.F., Shelton J., Richardson J.A., Stockinger W., et al. Interactions of the low density lipoprotein receptor gene family with cytosolic adaptor and scaffold proteins suggest diverse biological functions in cellular communication and signal transduction. J Biol Chem 2000, 275:25616-25624.
63. Nykjaer A., Willnow T.E. The low-density lipoprotein receptor gene family: a cellular Swiss army knife?. Trends Cell Biol 2002, 12:273-280.
64. Bafico A., Liu G., Yaniv A., Gazit A., Aaronson S.A. Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat Cell Biol 2001, 3:683-686.
65. Balemans W., Devogelaer J.P., Cleiren E., Piters E., Caussin E., Van Hul W. Novel LRP5 missense mutation in a patient with a high bone mass phenotype results in decreased DKK1-mediated inhibition of Wnt signaling. J Bone Miner Res 2007, 22:708-716.
66. Semenov M.V., Tamai K., Brott B.K., Kuhl M., Sokol S., He X. Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6. Curr Biol 2001, 11:951-961.
67. Brunkow M.E., Gardner J.C., Van Ness J., Paeper B.W., Kovacevich B.R., Proll S., et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 2001, 68:577-589.
68. Adamska M., MacDonald B.T., Meisler M.H. Doubleridge, a mouse mutant with defective compaction of the apical ectodermal ridge and normal dorsal-ventral patterning of the limb. Dev Biol 2003, 255:350-362.
69. Ahn Y., Sims C., Logue J.M., Weatherbee S.D., Krumlauf R. Lrp4 and Wise interplay controls the formation and patterning of mammary and other skin appendage placodes by modulating Wnt signaling. Development 2013, 140:583-593.
70. Klassen M.P., Shen K. Wnt signaling positions neuromuscular connectivity by inhibiting synapse formation in C. elegans. Cell 2007, 130:704-716.
71. Koles K., Budnik V. Wnt signaling in neuromuscular junction development. Cold Spring Harb Perspect Biol 2012, 4.
72. Korkut C., Ataman B., Ramachandran P., Ashley J., Barria R., Gherbesi N., et al. Trans-synaptic transmission of vesicular Wnt signals through Evi/Wntless. Cell 2009, 139:393-404.
73. Korkut C., Budnik V. WNTs tune up the neuromuscular junction. Nat Rev Neurosci 2009, 10:627-634.
74. Glass D.J., DeChiara T.M., Stitt T.N., DiStefano P.S., Valenzuela D.M., Yancopoulos G.D. The receptor tyrosine kinase MuSK is required for neuromuscular junction formation and is a functional receptor for agrin. Cold Spring Harb Symp Quant Biol 1996, 61:435-444.
75. Valenzuela D.M., Stitt T.N., DiStefano P.S., Rojas E., Mattsson K., Compton D.L., et al. Receptor tyrosine kinase specific for the skeletal muscle lineage: expression in embryonic muscle, at the neuromuscular junction, and after injury. Neuron 1995, 15:573-584.
76. Henriquez J.P., Webb A., Bence M., Bildsoe H., Sahores M., Hughes S.M., et al. Wnt signaling promotes AChR aggregation at the neuromuscular synapse in collaboration with agrin. Proc Natl Acad Sci U S A 2008, 105:18812-18817.
77. Barik A., Zhang B., Sohal G.S., Xiong W.C., Mei L. Crosstalk between Agrin and Wnt signaling pathways in development of vertebrate neuromuscular junction. Dev Neurobiol 2014, 74:828-838.
78. Jing L., Lefebvre J.L., Gordon L.R., Granato M. Wnt signals organize synaptic prepattern and axon guidance through the zebrafish unplugged/MuSK receptor. Neuron 2009, 61:721-733.
79. Strochlic L., Falk J., Goillot E., Sigoillot S., Bourgeois F., Delers P., et al. Wnt4 participates in the formation of vertebrate neuromuscular junction. PLoS One 2012, 7:e29976.
80. Khan T.N., Klar J., Ali Z., Khan F., Baig S.M., Dahl N. Cenani-Lenz syndrome restricted to limb and kidney anomalies associated with a novel LRP4 missense mutation. Eur J Med Genet 2013, 56:371-374.